KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Beginning Cash Balance: 2009-2024

Historic Beginning Cash Balance for Pacira BioSciences (PCRX) over the last 16 years, with Dec 2024 value amounting to $153.3 million.

  • Pacira BioSciences' Beginning Cash Balance rose 21.63% to $300.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $246.0 million, marking a year-over-year increase of 148.15%. This contributed to the annual value of $153.3 million for FY2024, which is 47.21% up from last year.
  • As of FY2024, Pacira BioSciences' Beginning Cash Balance stood at $153.3 million, which was up 47.21% from $104.1 million recorded in FY2023.
  • In the past 5 years, Pacira BioSciences' Beginning Cash Balance ranged from a high of $585.6 million in FY2022 and a low of $78.2 million during FY2020.
  • Its 3-year average for Beginning Cash Balance is $281.0 million, with a median of $153.3 million in 2024.
  • In the last 5 years, Pacira BioSciences' Beginning Cash Balance skyrocketed by 485.83% in 2022 and then crashed by 82.22% in 2023.
  • Yearly analysis of 5 years shows Pacira BioSciences' Beginning Cash Balance stood at $78.2 million in 2020, then grew by 27.78% to $100.0 million in 2021, then soared by 485.83% to $585.6 million in 2022, then slumped by 82.22% to $104.1 million in 2023, then skyrocketed by 47.21% to $153.3 million in 2024.